NCT03232632

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries.

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: University Hospital, Toulouse · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

Detailed description

Hypothesis had been performed that PET with 18F-Flutemetamol (Vizamyl®) could lead an early diagnostic. Indeed, this tracer had been recently used to highlight inter-cerebral beta-amyloid plaques on patients with Alzheimer Disease. Because this labelling is performed on amyloid deposits, this tracer would lead to view and to quantify amyloid deposits within cardiac amyloid injuries. Results of this PET will be combined with scan examinations for a better anatomic tracking.

Conditions

• Cardiac Amyloidosis

Interventions

Type	Name	Description
DRUG	PET with 18 F-Flutemetamol	PET with 18 F-Flutemetamol (Vizamyl ®)

Timeline

• Start date: 2017-03-15
• Primary completion: 2019-09-15
• Completion: 2019-09-15
• First posted: 2017-07-28
• Last updated: 2020-08-26

Locations

1 site across 1 country: France